Provexis plc (AIM: PXS)

Market Cap	14.75M
Revenue (ttm)	598.08K
Net Income (ttm)	-496.59K
Shares Out	2.26B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,301,065
Open	0.689
Previous Close	0.650
Day's Range	0.605 - 0.700
52-Week Range	0.413 - 0.900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2024

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company’s syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2022, Provexis's revenue was 389,916, a decrease of -8.51% compared to the previous year's 426,168. Losses were -385,241, 71.8% more than in 2021.